REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES

被引：0

作者：

Rizzardini, Giuliano ^{[1
]}

Gschwantler, Michael ^{[2
]}

Bourgeois, Stefan ^{[3
]}

Mullhaupt, Beat ^{[4
,5
]}

Mazur, Wlodzimierz ^{[6
]}

Bondin, Mark ^{[7
]}

Zhang, Zhenzhen ^{[7
]}

Marra, Fiona ^{[8
]}

Veitsman, Ella ^{[9
]}

Mimidis, Konstantinos ^{[10
]}

Marques, Nuno ^{[11
]}

Foucher, Juliette ^{[12
]}

机构：

[1] Asst Fatebenefratelli Sacco, Div Infect Dis 1, Milan, Italy

[2] Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria

[3] Stuivenberg Zna, Antwerp, Belgium

[4] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland

[5] Univ Zurich, Zurich, Switzerland

[6] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland

[7] Abbvie Inc, N Chicago, IL USA

[8] Univ Liverpool, Hepatol Drug Interact Grp, Liverpool, Merseyside, England

[9] Rambam Hlth Care Campus, Liver Unit, Haifa, Israel

[10] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Xanthi, Greece

[11] Hosp Garcia Orta Epe, Infect Dis Serv, Almada, Portugal

[12] Hop Haut Leveque, Pessac, France

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

929

引用

页码：568A / 569A

页数：2

共 47 条

[1] Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
Alessio Aghemo
Yves Horsmans
Stefan Bourgeois
Mark Bondin
Michael Gschwantler
Harald Hofer
Nasser Semmo
Francesco Negro
Zhenzhen Zhang
John Marcinak
Ella Veitsman
Rawi Hazzan
Konstantinos Mimidis
Ioannis Goulis
Nuno Marques
Robert Flisiak
Wlodzimierz Mazur
Carlos Roncero
Fiona Marra
Georges Philippe Pageaux
Tarik Asselah
Pietro Lampertico
Infectious Diseases and Therapy, 2021, 10 : 2203 - 2222
[2] Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
Aghemo, Alessio
Horsmans, Yves
Bourgeois, Stefan
Bondin, Mark
Gschwantler, Michael
Hofer, Harald
Semmo, Nasser
Negro, Francesco
Zhang, Zhenzhen
Marcinak, John
Veitsman, Ella
Hazzan, Rawi
Mimidis, Konstantinos
Goulis, Ioannis
Marques, Nuno
Flisiak, Robert
Mazur, Wlodzimierz
Roncero, Carlos
Marra, Fiona
Pageaux, Georges Philippe
Asselah, Tarik
Lampertico, Pietro
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2203 - 2222
[3] Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries
Lampertico, Pietro
Flisiak, Robert
Marques, Nuno
Clerc, Olivier
Goulis, Ioannis
Bondin, Mark
Porcalla, Ariel
Zhang, Zhenzhen
Horsmans, Yves
Hofer, Harald
Veitsman, Ella
Pageaux, Georges-Philippe
JOURNAL OF HEPATOLOGY, 2020, 73 : S358 - S359
[4] Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Hung, Chien-Ching
Hsieh, Szu-Min
Su, Tung-Hung
Sun, Hsin-Yun
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
LIVER INTERNATIONAL, 2020, 40 (04) : 758 - 768
[5] Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland
Mullhaupt, Beat
Semela, David
Ruckstuhl, Lisa
Magenta, Lorenzo
Clerc, Olivier
Torgler, Ralph
Negro, Francesco
Semmo, Nasser
SWISS MEDICAL WEEKLY, 2021, 151
[6] ADDRESSING BARRIERS TO HEPATITIS C VIRUS (HCV) ELIMINATION: REAL-WORLD OUTCOMES IN HISTORICALLY UNDERSERVED PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR
Lampertico, Pietro
Peck-Radosavljevic, Markus
Bondin, Mark I.
Mazur, Wlodzimierz
Magenta, Lorenzo
Foucher, Juliette
Porcalla, Ariel
Crown, Eric D.
Jalundhwala, Yash
Zhang, Zhenzhen
Mimidis, Konstantinos
Hazzan, Rawi
Marques, Nuno
Bourgeois, Stefan
HEPATOLOGY, 2019, 70 : 954A - 955A
[7] Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study
Aghemo, Alessio
Alberti, Alfredo
Andreone, Pietro
Angelico, Mario
Brunetto, Maurizia Rossana
Chessa, Luchino
Ciancio, Alessia
Craxi, Antonio
Gaeta, Giovanni Battista
Galli, Massimo
Gasbarrini, Antonio
Giorgini, Alessia
Grilli, Elisabetta
Lampertico, Pietro
Lichtner, Miriam
Milella, Michele
Morisco, Filomena
Persico, Marcello
Pirisi, Mario
Puoti, Massimo
Raimondo, Giovanni
Romano, Antonietta
Russello, Maurizio
Sangiovanni, Vincenzo
Schiavini, Monica
Serviddio, Gaetano
Villa, Erica
Vinci, Maria
De Michina, Antonella
Gallinaro, Valentina
Gualberti, Giuliana
Roscini, Antonio Saverio
Zignego, Anna Linda
DIGESTIVE AND LIVER DISEASE, 2021, 53 (05) : 612 - 619
[8] REAL-WORLD EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A META-ANALYSIS
Cornberg, Markus
Negro, Francesco
Lampertico, Pietro
Turnes, Juan
Curry, Michael P.
Brown, Ashley
Wedemeyer, Heiner
Carrion, Jose A.
Wick, Nicole
Pangerl, Andreas
GUT, 2019, 68 : A147 - A147
[9] Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis
Cornberg, Markus
Negro, Francesco
Lampertico, Pietro
Turnes, Juan
Curry, Michael
Brown, Ashley
Wedemeyer, Heiner
Antonio Carrion, Jose
Wick, Nicole
Pangerl, Andreas
Larsen, Lois
Yu, Yao
Persico, Marcello
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E113 - E114
[10] REAL-WORLD EXPERIENCE OF GLECAPREVIR/PIBRENTASVIR TREATMENT IN JAPANESE ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY
Mizuochi, Tatsuki
Iwama, Itaru
Inui, Ayano
Ito, Yoshinori
Takaki, Yugo
Mushiake, Sotaro
Tokuhara, Daisuke
Ishige, Takashi
Ito, Koichi
Murakami, Jun
Hishiki, Haruka
Mikami, Hitoshi
Bessho, Kazuhiko
Kato, Ken
Yasuda, Ryosuke
Yamashita, Yushiro
Tanaka, Yasuhito
Tajiri, Hitoshi
HEPATOLOGY, 2022, 76 : S1524 - S1525

← 1 2 3 4 5 →